Showing papers by "Michael J. Rieder published in 1997"
TL;DR: This statement has been updated and its information expanded because some of the reported adverse reactions are no longer considered clinically significant, and other new reactions have emerged.
Abstract: Because of an increasing number of reports of adverse reactions associated with pharmaceutical excipients, in 1985 the Committee on Drugs issued a position statement recommending that the Food and Drug Administration mandate labeling of over-the-counter and prescription formulations to include a qualitative list of inactive ingredients. However, labeling of inactive ingredients remains voluntary. Adverse reactions continue to be reported, although some are no longer considered clinically significant, and other new reactions have emerged. The original statement, therefore, has been updated and its information expanded.
150 citations
TL;DR: An analysis of the current status of the use of human growth hormone in children with a focus on children with growth hormone deficiency is presented.
Abstract: Since 1985 molecular biology techniques have made possible the synthetic synthesis of pure human growth hormone in potentially unlimited amounts. With this increased availability, its use in patients other than children with growth hormone deficiency has been associated with clinical and ethical questions. This statement presents an analysis of the current status of the use of human growth hormone in children.
54 citations